Asthma and COPD Drugs Market Trends

Growth Drivers

Rising prevalence of Asthma and COPD – The growth of the asthma and COPD drugs market is mainly driven by the increasing prevalence of COPD and asthma. For example, according to data stated by the World Health Organization (WHO) in 2019, asthma affected about 262 million population. Moreover, according to the fact stated by American Lung Organization in 2018, 99 million people in the United States have chronic bronchitis.
Development in Respiratory Diseases Therapeutics – There has been increasing in the launch of new products for the medication of chronic obstructive pulmonary diseases. For example, AstraZenca, obtained European approval for "Trixeo Aerosphere" for the maintenance cure of COPD.
Increasing healthcare expenditure – Healthcare expenditure is on the rise globally, driven by factors such as population growth, aging, and the increasing burden of chronic diseases.

Challenges

Patent Expirations – Many of the blockbuster drugs used to treat respiratory diseases are coming off patent, which is leading to increased competition from generic drugs. This is likely to reduce the revenue of branded drugs and increase pressure on drug manufacturers to develop new and innovative drugs.
High cost of drugs
Adverse effects of drugs

Asthma and COPD Drugs Market: Key Insights

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Base Year	2024
Forecast Year	2025-2037
CAGR	7.7%
Base Year Market Size (2024)	USD 40.5 billion
Forecast Year Market Size (2037)	USD 105.44 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of asthma and COPD drugs is evaluated at USD 43.03 billion.

The asthma and COPD drugs market size was over USD 40.5 billion in 2024 and is anticipated to exceed USD 105.44 billion by the end of 2037, witnessing over 7.7% CAGR during the forecast period i.e., between 2025-2037. High prevalence and incidence of asthma and COPD, decreasing environmental air quality, and the presence of harmful gases and particles will boost the market growth.

North American industry will hold the largest share by 2037, as growing healthcare infrastructure in the region is able to provide the required treatment to the patients.

The major players in the market include GlaxoSmithKline plc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, CHIESI Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Abbott.

Asthma and COPD Drugs Market Trends